We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 1.50 | 8.70% | 18.75 | 1,492,759 | 16:24:14 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 18.50 | 19.00 | 18.75 | 17.25 | 17.25 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0125 | -15.00 | 39M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:29:38 | O | 19,016 | 18.90 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 12/12/2024 | 14:45 | UK RNS | SkinBioTherapeutics PLC Holding(s) in Company |
| 04/12/2024 | 15:55 | UK RNS | SkinBioTherapeutics PLC Posting of Annual Report and Notice of AGM |
| 04/12/2024 | 15:54 | UK RNS | SkinBioTherapeutics PLC Final Results |
| 04/12/2024 | 07:00 | UK RNS | SkinBioTherapeutics PLC Notice of Results |
| 29/11/2024 | 11:00 | UK RNS | SkinBioTherapeutics PLC Notice of Results |
| 19/11/2024 | 07:00 | UK RNS | SkinBioTherapeutics PLC Finalisation of commercial agreement with Croda |
| 25/10/2024 | 15:29 | UK RNS | SkinBioTherapeutics PLC Holding(s) in Company |
| 23/10/2024 | 15:34 | ALNC |  IN BRIEF: SkinBioTherapeutics boosts financial 2025 turnover forecast |
| 23/10/2024 | 13:40 | UK RNS | SkinBioTherapeutics PLC Integration update and share price movement |
| 17/10/2024 | 06:00 | UK RNS | SkinBioTherapeutics PLC Holding(s) in Company |
Skinbiotherapeutics (SBTX) Share Charts1 Year Skinbiotherapeutics Chart |
|
1 Month Skinbiotherapeutics Chart |
Intraday Skinbiotherapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 13/12/2024 | 21:26 | SkinBioTherapeutics PLC - Multi $bn skin health opportunities. | 21,009 |
| 13/12/2024 | 19:36 | SkinBioTherapeutics PLC | 6,618 |
| 03/12/2024 | 13:52 | The new Matrixyl set to revolutionise skin care | 101 |
| 23/9/2024 | 15:08 | Sbtx going forward | 5 |
| 16/6/2024 | 11:21 | Senti-mentalRiles - Joseph Sheedy | 195 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 16:29:40 | 18.90 | 19,016 | 3,594.02 | O |
| 16:28:05 | 18.63 | 32,337 | 6,025.19 | O |
| 16:27:33 | 18.63 | 12,000 | 2,235.90 | O |
| 16:20:18 | 18.99 | 52,621 | 9,994.04 | O |
| 16:20:11 | 18.45 | 9,253 | 1,707.07 | O |
| Top Posts |
|---|
Posted at 13/12/2024 08:20 by Skinbiotherapeutics Daily Update Skinbiotherapeutics Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker SBTX. The last closing price for Skinbiotherapeutics was 17.25p.Skinbiotherapeutics currently has 226,086,285 shares in issue. The market capitalisation of Skinbiotherapeutics is £42,391,178. Skinbiotherapeutics has a price to earnings ratio (PE ratio) of -15.00. This morning SBTX shares opened at 17.25p |
Posted at 12/12/2024 11:23 by putinaire Most of the time, all a maker has to do for the sell instructions, is drive price to where liquidity will exist. Very common.But forgetting all that, you now are in a scenario as a holder, of share price having too much work to do to rise further ie it's where the sellers want it, and 2. less likely liquidity on another run, so not worth makers while going back to0 soon. The only way you can break the above prices now is 2 fold 1. no-news false market creation, or. 2. news (still be false market creation) Point is, market never takes it up to liquidity prices. It's the maker that does, to make a 'sell' market for clients |
Posted at 11/12/2024 12:59 by putinaire Anyway back to share price and money.SBTX on average, falls 70% on divergence counts, investor timeframe. This week we have the biggest number ever forming - so, shorters will be thinking a safe -50% at least into Q1 2025 That rule only ever breaks when news comes of note. Problem is though, once you see %s like today on no news, well, you know no news coming to stop the expected market occuring |
Posted at 10/12/2024 08:44 by pr100 Some people forget that the beauty and personal care market is in the process of shifting to the kind of bio solutions which have been developed and patented by SBTX. So Skin's sub-sector should comfortably outperform the overall 3.8% projected annual growth rate - which is a healthy growth rate for such a well developed business.Warren Buffet said that shrewd investors bought shares in spade manufacturers rather than gold miners. SBTX make the tools for Croda et al to go prospecting for nuggets. And since SBTX start from zero, it won't much matter to them whether the total market declines or not. And while we don't know what the Croda deal will be worth, we do know that it is signed and sealed which is a huge turbo boost to get at today's cheap buy-in price - no matter whether year 1 revenues are £100k, £1m or £10m. Croda are convinced about the value of Skin's IP and have committed to buy. That in turn will grow the valuation of Skin's IP. It's on a plate. And it is very rare to get such a gift-wrapped investment opportunity in the micro-cap space on the AIM market. While the future may see a fundraise to buy a new acquisition, Skin's CEO has stated that the Croda launch plan and forecast would make it unnecessary to ever again come back to the market for working capital purposes. Sure, it's possible that Croda don't know what they are doing or that their forecasts have been inflated to get better terms or that Covid or WW3 will stop the world again; but SBTX have other fish to fry too. All investments are gambles but I don't see many better punts around than SBTX. |
Posted at 09/12/2024 14:48 by pr100 Is the Croda deal real? Will SBTX start seeing revenues from Croda imminently? Are Croda lying about their own SBTX trials? Is Croda just messing around by seconding Dr Surinder Chahal to advise the SBTX Board?Don't confuse Croda with some PT Barnum AIM chancer. And stop fretting about how much SBTX will earn from the deal. The next reports and accounts will tell you how much. |
Posted at 09/12/2024 11:04 by putinaire Do not forget the track record here re:A past product launch that spiked price, and let opti dump near on half the float on gerbils at extortionate prices. Once done? Back to single digit share price for cash raises and CLN's. And of course, high share price gerbil holdings to get smashed/diluted. What a set up So if you ask me to now believe that the CEO is worth backing wholly blind, even though an obvious opti puppet? LOLOL Again i ask any buyers, what exactly are you investing in today? It isnt a new product you know anything about. It is not forecasts. It certainly is not track record. It sure as hell aint financials. It can't be acquisitions (do research on value via goodwill, and similar competitor average net earnings YoY) What are you investing in? Be clear about it |
Posted at 28/10/2024 21:48 by kreature Sold a few due to 100k chunks getting creamed offWas there another ‘Share Price Movement’ RNS ? ‘we know of no reason for the rise’ ? lol Or are they not bothered if the share price follows a script ? |
Posted at 23/10/2024 18:45 by kreature RNS Translation‘No reason for share price movement’ Translation: What is going on ? ‘ No rationale for share price movement ‘ Translation: We don’t understand, we have no clue, help ‘ to the Board's knowledge, there is no reason behind it.’ Translation: ‘We don’t understand that more selling pressure than buying, can be a reason for a share price to be marked lower ‘ Imo |
Posted at 23/10/2024 18:25 by kreature ‘ No rationale for share price movement ‘For balance, I’d say the rational could be…. 1. Profit taking following a 50% share price rise 2. Uncertainty concerning the Opti situation 3. Investors understanding that turnover is not net profit 4. Just a general sense of binaryness in the air. In my opinion, as always. |
Posted at 23/10/2024 18:15 by kreature RNS sub titles looks a bit desperate given stated twice below, imv tbf. In fairness, I bet some systems just don’t work unless the share price remains within a distribution zone ? Also tbf turnover is not earnings right ?‘No reason for share price movement’ ‘No rationale for share price movement ‘ |
Posted at 15/10/2024 09:44 by cowickhaller All playing out exactly as I thought.Great that SBTX now have a ‘Croda insider’ on board, that will level things up somewhat. There were things in the podcast that have not really been picked up on. A few examples. SBTX & Croda are planning further collaborations. This ties SBTX in further with Croda and together they could be a real powerhouse in their chosen field. SA talked about Matrixyl and replacing it. SA has to be careful with what he says, understandably so, but listen to the mood music and watch the body language. Finally SA talks about not resting till the SBTX share price is over £1. I fully endorse his conservatism. If this takes off as expected, we are certainly talking multiples of that. With the CRDA share price bouncing around the lows, CRDA need this development to succeed and it will. It’s not often industrial chemical companies like CRDA make the news, unless it’s for the wrong reasons. I predict it will happen here for the right reasons, April 2025. A blink of an eye for seasoned investors but a lifetime for some. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
